May 05, 2022 7:00am EDT Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
Apr 28, 2022 7:00am EDT Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
Mar 03, 2022 8:30am EST Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Feb 01, 2022 8:30am EST Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
Jan 10, 2022 7:00am EST Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
Dec 15, 2021 8:30am EST Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
Oct 21, 2021 8:30am EDT Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
